Why Is SLS Stock Drawing Significant Investor Attention Today?

Maxim analyst Jason McCarthy noted that because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the effectiveness of GPS.

• The company said that 72 out of the prespecified 80 deaths required to trigger the final analysis have now occurred as of Dec. 26, 2025.
• That extended survival timeline may delay the anticipated year-end 2025 reporting, but could indicate positive treatment impact if unblinded data confirms it.
• The REGAL trial’s final scrutiny depends on reaching the event threshold.

SELLAS Life Sciences Group Inc.’s (SLS) shares were in the spotlight on Wednesday after Maxim took an optimistic position regarding the Phase 3 clinical trial of galinpepimut-S (GPS) for acute myeloid leukemia (AML). 

The study’s contract research organization has informed the company that 72 out of the prespecified 80 patient deaths required to trigger the final analysis have now occurred as of Dec. 26, 2025.

Implications Of Delayed Trigger

Maxim analyst Jason McCarthy noted that because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the effectiveness of GPS. 

That extended survival timeline may delay the anticipated year-end 2025 reporting but could indicate positive treatment impact if unblinded data confirms it, added the firm. 

SELLAS Life Sciences’ stock traded over 4% higher on Wednesday mid-morning. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels. 

Event-Driven Analysis

The ongoing GPS trial is an overall survival study, and the final analysis is expected once 80 deaths have occurred. 

“We appreciate the continued dedication of the patients, families, and investigators participating in the pivotal Phase 3 REGAL trial where survival times, fortunately for patients and caregivers, appear longer than expected,” said SELLAS CEO Angelos Stergiou on Monday. “While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&D event.”

GPS is SELLAS’ main drug candidate, and it works by targeting the WT1 protein found in many different cancers. The company is currently evaluating the drug as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.

SLS stock has gained over 234% year-to-date. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.<